Ipsen $1.31 billion acquisition of Clementia Pharmaceuticals

Overview:

• Paris-based pharmaceutical company Ipsen has acquired Canadian company Clementia Pharmaceuticals in a $1.31 billion deal. 
• Clementia focuses on developing drug treatments for bone disorders. 
• Morgan Stanley is acting as financial adviser to Clementia while Centerview Partners is acting for Ipsen. 
• The transaction is expected to close in the second quarter of 2019. 

Kurt Stumpo - US Editor